| Literature DB >> 31371929 |
Stijn L Steunenberg1, Jolanda de Vries2,3, Jelle W Raats1, Nathalie Verbogt1, Paul Lodder2,4, Geert-Jan van Eijck5, Eelco J Veen1, Hans Gw de Groot1, Gwan H Ho1, Lijckle van der Laan1.
Abstract
INTRODUCTION: Critical limb ischemia (CLI) patients are often of advanced age with reduced health status (HS) and quality of life (QoL) at baseline. Physical health is considered as the most affected domain due to reduced mobility and ischemic pain. QoL and HS are often used interchangeably in the current literature. HS refers to objectively perceived physical, psychological, and social functioning and in assessing QoL, change is measured subjectively and can only be determined by the individual since it concerns patients' evaluation of their functioning. It is important to distinguish between QoL and HS, especially in the concept of shared decision-making when the opinion of the patient is key. Goal of this study was to examine and compare QoL and HS in elderly CLI patients in relation to the used therapy, with a special interest in conservatively treated patients.Entities:
Keywords: critical limb ischemia; elderly; health status; quality of life
Mesh:
Year: 2019 PMID: 31371929 PMCID: PMC6626895 DOI: 10.2147/CIA.S202725
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Baseline characteristics
| Endovascular (n=82) | Surgical (n=67) | Conservative (n=46) | |
|---|---|---|---|
| Sex (male) | 45 (55) | 44 (66) | 21 (46) |
| Age (median) (IQR) | 81 (10) | 76 (8) | 83 (9) *,# |
| Rutherford 4 | 22 (27) | 36 (54) | 6 (13) *,# |
| Rutherford 5/6 | 60 (73) | 31 (46) | 40 (87) |
| Pulmonary comorbidity | 54 (68) | 28 (42) | 26 (58) * |
| Cardiac comorbidity | 62 (76) | 36 (54) | 36 (78) *,# |
| Neurologic comorbidity | 23 (28) | 19 (28) | 21 (46) ^ |
| Arthritis | 21 (26) | 17 (25) | 20 (44) ^,# |
| Hypertension | 62 (76) | 39 (58) | 29 (64)* |
| Diabetes | 49 (60) | 22 (33) | 23 (50)* |
| Renal impairment | 55 (67) | 23 (34) | 33 (72)*,# |
| Current smoking | 15 (19) | 23 (34) | 7 (16)*,# |
Notes: Data are presented as n and (%), unless otherwise specified. Pulmonary comorbidity: asthma/chronic obstructive pulmonary disease. Cardiac comorbidity: angina/myocardial infarction/heart failure/arrhythmias. Neurologic comorbidity: transient ischemic attack/cerebrovascular accident. *Significant difference between endovascular and surgical treated patients (P<0.05). ^Significant difference between endovascular and conservative treated patients (P<0.05). #Significant difference between surgical and conservative treated patients (P<0.05).
Abbreviation: IQR, interquartile range.
WHOQoL-Bref vs SF12 according to received treatment
| Endovascular (n=82) | Surgical (n=67) | Conservative (n=46) | |
|---|---|---|---|
| Baseline | 10.9 (2.9) | 10.4 (2.5) | 11.6 (2.9) |
| 5–7 days | 11.9 (3.1)* | 12.1 (2.6)* | 12.1 (2.7) |
| 6 weeks | 12.4 (3.3)** | 13.5 (3.0)** | 11.8 (3.1) |
| 6 months | 13.6 (3.1)*** | 14.5 (2.2)*** | 13.2 (2.6)*** |
| 1 year | 13.7 (2.8) **** | 14.9 (2.5) **** | 13.2 (2.9) **** |
| Baseline | 28.9 (9.3) | 28.0 (6.7) | 30.2 (10.3) |
| 5–7 days | 29.2 (9.8) | 28.9 (7.3) | 28.7 (8.8) |
| 6 weeks | 31.5 (10.3) | 34.2 (9.2) ** | 28.3 (8.8) |
| 6 months | 35.4 (9.8) *** | 38.0 (9.4) *** | 30.9 (8.0) |
| 1 year | 35.3 (10.8) **** | 37.3 (9.6) **** | 31.4 (9.3) |
| Baseline | 14.2 (2.5) | 14.0 (2.4) | 14.1 (2.5) |
| 5–7 days | 14.6 (1.9) | 14.7 (2.2)* | 14.5 (1.6) |
| 6 weeks | 14.7 (2.1) | 14.8 (2.2)** | 14.1 (2.3) |
| 6 months | 14.7 (1.8) | 15.2 (1.9)*** | 14.5 (1.8) |
| 1 year | 14.8 (2.1) | 15.3 (1.9) **** | 14.0 (2.3) |
| Baseline | 37.0 (11.7) | 36.1 (10.3) | 40.1 (11.2) |
| 5–7 days | 40.2 (8.3) | 40.5 (9.0) * | 40.5 (7.8) |
| 6 weeks | 39.6 (9.7) | 42.0 (7.4) ** | 40.6 (7.5) |
| 6 months | 42.4 (7.3) *** | 44.1 (7.6) *** | 37.6 (7.3) |
| 1 year | 42.5 (8.7) | 43.9 (7.7) **** | 39.5 (10.5) |
Notes: Data are presented as mean and standard deviation. *Significant difference in the treatment group between Baseline and 5–7 days follow-up. **Significant difference in the treatment group between Baseline and 6-week follow-up. ***Significant difference in the treatment group between Baseline and 6-month follow-up. ****Significant difference in the treatment group between Baseline and 1-year follow-up. Missing values due to loss of follow-up: 5–7 days =22 missing values, 6 weeks =20 missing values, 6 months =21 missing values 12 months =20 missing values.
Abbreviations: QoL, Quality of Life (WHOQoL-Bref); HS, Health Status (SF-12).
Questions asked in the questionnaires
| Domain | WHO-QoL Bref | SF-12 |
|---|---|---|
| Physical | How satisfied are you with your ability to perform your daily living activities? | Are you now limited in moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf? Does your health now limit you a lot, limit you a little or not limit you at all? |
| Physical | To what extent do you feel that physical pain prevents you from doing what you need to do? | During the past four weeks, how much did pain interfere with your normal work including both outside the home and housework? |
| Psychological | How much do you enjoy life? | How much of the time during the past four weeks did you have a lot of energy? |